Patents by Inventor Michael Solomon Goldberg
Michael Solomon Goldberg has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20240082236Abstract: Provided herein are technologies suitable for the treatment of certain immunologically related disorders.Type: ApplicationFiled: January 28, 2022Publication date: March 14, 2024Inventor: Michael Solomon Goldberg
-
Publication number: 20240076309Abstract: The present invention provides circularized RNA and methods of making, purifying, and using same.Type: ApplicationFiled: July 24, 2023Publication date: March 7, 2024Inventors: Michael Solomon Goldberg, Ellese Carmona
-
Publication number: 20230398146Abstract: The present disclosure provides technologies related to compositions each comprising a biomaterial preparation and a modulator of myeloid-derived suppressive cell function (e.g., a modulator of neutrophil function) as well as uses thereof for cancer treatment.Type: ApplicationFiled: August 17, 2021Publication date: December 14, 2023Inventor: Michael Solomon Goldberg
-
Publication number: 20230293427Abstract: The present disclosure provides technologies related to certain polymer combination preparations and uses thereof. In many embodiments, such polymer combination preparations are temperature-responsive. In some embodiments, such polymer combination preparations may be useful as immunomodulatory biomaterials, e.g, to induce innate immunity or to resolve inflammation (e.g.; immunosuppressive inflammation). In some embodiments, such polymer combination preparations may be useful to formulate compositions comprising active agent(s).Type: ApplicationFiled: July 17, 2021Publication date: September 21, 2023Inventors: Michael Solomon Goldberg, Paul Adam Konowicz, Ivy Xiaoyu Chen
-
Patent number: 11753434Abstract: The present invention provides circularized RNA and methods of making, purifying, and using same.Type: GrantFiled: April 13, 2018Date of Patent: September 12, 2023Assignee: Dana-Farber Cancer Institute, Inc.Inventors: Michael Solomon Goldberg, Eliese Carmona
-
Publication number: 20220218822Abstract: The present disclosure provides technologies for treatment and/or prevention of cancer and metastatic tumors. For example, in some embodiments, a biomaterial (e.g., polymeric biomaterial) or scaffold that can stimulate innate immunity is administered in the absence of an immunomodulatory payload to a target site in a subject following tumor removal (e.g., by surgical resection). Such technologies can reduce or inhibit incidence of tumor regrowth and/or metastasis.Type: ApplicationFiled: May 1, 2020Publication date: July 14, 2022Inventor: Michael Solomon Goldberg
-
Publication number: 20210246211Abstract: Provided are drug delivery compositions and devices useful for the treatment and/or prevention of cancer and metastatic tumors. For example, a drug delivery device is provided that comprises a biodegradable scaffold carrying one or more anti-cancer therapeutic agents that activate the innate immune system (e.g., STING agonists) and/or the adaptive immune system (e.g., anti-PD-1 antibodies). The compositions and devices may include a cytokine (e.g., IL-15 superagonist). The drug delivery device can be implanted in the void volume of a resected tumor to prevent tumor regrowth and tumor metastasis. Also provided are methods of making the drug delivery compositions and devices as well as kits containing materials to provide the compositions and devices.Type: ApplicationFiled: April 27, 2021Publication date: August 12, 2021Applicant: Dana-Farber Cancer Institute, Inc.Inventors: Michael Solomon Goldberg, Chun Gwon Park
-
Patent number: 11021539Abstract: Provided are drug delivery compositions and devices useful for the treatment and/or prevention of cancer and metastatic tumors. For example, a drug delivery device is provided that comprises a biodegradable scaffold carrying one or more anti-cancer therapeutic agents that activate the innate immune system (e.g., STING agonists) and/or the adaptive immune system (e.g., anti-PD-1 antibodies). The compositions and devices may include a cytokine (e.g., IL-15 superagonist). The drug delivery device can be implanted in the void volume of a resected tumor to prevent tumor regrowth and tumor metastasis. Also provided are methods of making the drug delivery compositions and devices as well as kits containing materials to provide the compositions and devices.Type: GrantFiled: August 1, 2019Date of Patent: June 1, 2021Assignee: Dana-Farber Cancer Institute, Inc.Inventors: Michael Solomon Goldberg, Chun Gwon Park
-
Publication number: 20210047360Abstract: The present invention provides circularized RNA and methods of making, purifying, and using same.Type: ApplicationFiled: April 13, 2018Publication date: February 18, 2021Applicant: Dana-Farber Cancer Institute, Inc.Inventors: Michael Solomon Goldberg, Ellese Carmona
-
Publication number: 20210008048Abstract: Provided are drug delivery compositions and devices useful for the treatment and/or prevention of cancer and metastatic tumors. For example, a drug delivery composition and/or device is provided that comprises a biodegradable scaffold or biomaterial comprising one or more agents that inhibit one or more proinflammatory pathways, such as one or more immune responses mediated by a p38 mitogen-activated protein kinase (MAPK) pathway. In some embodiments, a drug delivery composition and/or device may further comprise one or more agents that activate the innate immune system (e.g., STING agonists) and/or the adaptive immune system (e.g., anti-PD-1 antibodies). In some embodiments, a drug delivery composition and/or device may include a cytokine (e.g., IL-15 superagonist). In some embodiments, a drug delivery composition and/or device can be administered to a tumor resection site (e.g., a void volume resulting from a tumor resection).Type: ApplicationFiled: March 20, 2019Publication date: January 14, 2021Applicant: Dana-Farber Cancer Institute, Inc.Inventor: Michael Solomon Goldberg
-
Patent number: 10836826Abstract: Provided are drug delivery compositions and devices useful for the treatment and/or prevention of cancer and metastatic tumors. For example, a drug delivery device is provided that comprises a biodegradable scaffold carrying one or more anti-cancer therapeutic agents that activate the innate immune system (e.g., STING agonists) and/or the adaptive immune system (e.g., anti-PD-1 antibodies). The compositions and devices may include a cytokine (e.g., IL-15 superagonist). The drug delivery device can be implanted in the void volume of a resected tumor to prevent tumor regrowth and tumor metastasis. Also provided are methods of making the drug delivery compositions and devices as well as kits containing materials to provide the compositions and devices.Type: GrantFiled: August 26, 2019Date of Patent: November 17, 2020Assignee: Dana-Farber Cancer Institute, Inc.Inventors: Michael Solomon Goldberg, Chun Gwon Park
-
Publication number: 20200179528Abstract: The present disclosure provides particles with a polymeric core containing a pharmaceutically active agent; and an antibody fragment conjugated to the surface of the particle, wherein the antibody fragment targets an endogenous immune cell subset (e.g., an endogenous T-cell or a myeloid-derived suppressor cell). The present invention provides methods for forming and methods for using the particles. The particles described herein may be useful in treating and/or preventing proliferative disease, inflammatory disease, or neoplastic disorders (e.g., cancer, autoimmune diseases). Also provided in the present disclosure are pharmaceutical compositions, kits, methods, and uses including or using a particle described herein.Type: ApplicationFiled: December 23, 2016Publication date: June 11, 2020Applicants: Dana-Farber Cancer Institute, Inc., Massachusetts Institute of TechnologyInventors: Michael Solomon Goldberg, Daniela Schmid, Darrell J. Irvine, Kai Wucherpfennig
-
Publication number: 20200031930Abstract: Provided are drug delivery compositions and devices useful for the treatment and/or prevention of cancer and metastatic tumors. For example, a drug delivery device is provided that comprises a biodegradable scaffold carrying one or more anti-cancer therapeutic agents that activate the innate immune system (e.g., STING agonists) and/or the adaptive immune system (e.g., anti-PD-1 antibodies). The compositions and devices may include a cytokine (e.g., IL-15 superagonist). The drug delivery device can be implanted in the void volume of a resected tumor to prevent tumor regrowth and tumor metastasis. Also provided are methods of making the drug delivery compositions and devices as well as kits containing materials to provide the compositions and devices.Type: ApplicationFiled: August 1, 2019Publication date: January 30, 2020Applicant: Dana-Farber Cancer Institute, Inc.Inventors: Michael Solomon Goldberg, Chun Gwon Park
-
Publication number: 20190382492Abstract: Provided are drug delivery compositions and devices useful for the treatment and/or prevention of cancer and metastatic tumors. For example, a drug delivery device is provided that comprises a biodegradable scaffold carrying one or more anti-cancer therapeutic agents that activate the innate immune system (e.g., STING agonists) and/or the adaptive immune system (e.g., anti-PD-1 antibodies). The compositions and devices may include a cytokine (e.g., IL-15 superagonist). The drug delivery device can be implanted in the void volume of a resected tumor to prevent tumor regrowth and tumor metastasis. Also provided are methods of making the drug delivery compositions and devices as well as kits containing materials to provide the compositions and devices.Type: ApplicationFiled: August 26, 2019Publication date: December 19, 2019Applicant: Dana-Farber Cancer Institute, Inc.Inventors: Michael Solomon Goldberg, Chun Gwon Park
-
Patent number: 10435469Abstract: Provided are drug delivery compositions and devices useful for the treatment and/or prevention of cancer and metastatic tumors. For example, a drug delivery device is provided that comprises a biodegradable scaffold carrying one or more anti-cancer therapeutic agents that activate the innate immune system (e.g., STING agonists) and/or the adaptive immune system (e.g., anti-PD-1 antibodies). The compositions and devices may include a cytokine (e.g., IL-15 superagonist). The drug delivery device can be implanted in the void volume of a resected tumor to prevent tumor regrowth and tumor metastasis. Also provided are methods of making the drug delivery compositions and devices as well as kits containing materials to provide the compositions and devices.Type: GrantFiled: November 15, 2018Date of Patent: October 8, 2019Assignee: Dana-Farber Cancer Institute, Inc.Inventors: Michael Solomon Goldberg, Chun Gwon Park
-
Patent number: 10413612Abstract: Provided are drug delivery compositions and devices useful for the treatment and/or prevention of cancer and metastatic tumors. For example, a drug delivery device is provided that comprises a biodegradable scaffold carrying one or more anti-cancer therapeutic agents that activate the innate immune system (e.g., STING agonists) and/or the adaptive immune system (e.g., anti-PD-1 antibodies). The compositions and devices may include a cytokine (e.g., IL-15 superagonist). The drug delivery device can be implanted in the void volume of a resected tumor to prevent tumor regrowth and tumor metastasis. Also provided are methods of making the drug delivery compositions and devices as well as kits containing materials to provide the compositions and devices.Type: GrantFiled: November 15, 2018Date of Patent: September 17, 2019Assignee: Dana-Farber Cancer Institute, Inc.Inventors: Michael Solomon Goldberg, Chun Gwon Park
-
Publication number: 20190153098Abstract: Provided are drug delivery compositions and devices useful for the treatment and/or prevention of cancer and metastatic tumors. For example, a drug delivery device is provided that comprises a biodegradable scaffold carrying one or more anti-cancer therapeutic agents that activate the innate immune system (e.g., STING agonists) and/or the adaptive immune system (e.g., anti-PD-1 antibodies). The compositions and devices may include a cytokine (e.g., IL-15 superagonist). The drug delivery device can be implanted in the void volume of a resected tumor to prevent tumor regrowth and tumor metastasis. Also provided are methods of making the drug delivery compositions and devices as well as kits containing materials to provide the compositions and devices.Type: ApplicationFiled: November 15, 2018Publication date: May 23, 2019Applicant: Dana-Farber Cancer Institute, Inc.Inventors: Michael Solomon Goldberg, Chun Gwon Park
-
Publication number: 20190083626Abstract: Provided are drug delivery compositions and devices useful for the treatment and/or prevention of cancer and metastatic tumors. For example, a drug delivery device is provided that comprises a biodegradable scaffold carrying one or more anti-cancer therapeutic agents that activate the innate immune system (e.g., STING agonists) and/or the adaptive immune system (e.g., anti-PD-1 antibodies). The compositions and devices may include a cytokine (e.g., IL-15 superagonist). The drug delivery device can be implanted in the void volume of a resected tumor to prevent tumor regrowth and tumor metastasis. Also provided are methods of making the drug delivery compositions and devices as well as kits containing materials to provide the compositions and devices.Type: ApplicationFiled: November 15, 2018Publication date: March 21, 2019Applicant: Dana-Farber Cancer Institute, Inc.Inventors: Michael Solomon Goldberg, Chun Gwon Park
-
Publication number: 20180369407Abstract: The present disclosure provides particles with a polymeric core containing a pharmaceutically active agent; and an antibody fragment conjugated to the surface of the particle, wherein the antibody fragment targets an endogenous immune cell subset (e.g., an endogenous T-cell or a myeloid-derived suppressor cell). The present invention provides methods for forming and methods for using the particles. The particles described herein may be useful in treating and/or preventing proliferative disease, inflammatory disease, or neoplastic disorders (e.g., cancer, autoimmune diseases). Also provided in the present disclosure are pharmaceutical compositions, kits, methods, and uses including or using a particle described herein.Type: ApplicationFiled: December 23, 2016Publication date: December 27, 2018Applicants: Dana-Farber Cancer Institute, Inc., Massachusetts Institute of TechnologyInventors: Michael Solomon Goldberg, Daniela Schmid, Darrell J. Irvine, Kai Wucherpfennig
-
Publication number: 20170266123Abstract: In one aspect, a particle comprising a core containing at least one pharmaceutically active agent and a coating covering the surface of the particle that comprises a biocompatible adhesive polymer is provided. The core may comprise two or more components, such as two pharmaceutically active agents or a pharmaceutically active agent and a major constituent of the core, having at least one dissimilar chemical or physical property (e.g., molecular weight, solubility, c Log P). In some such embodiments, placement of the uncoated core in certain environments results in the rapid release of a component (e.g., a pharmaceutically active agent) from and/or destabilization and breakdown of the core. In some embodiments, the biocompatible adhesive polymer in the coating acts as a molecular glue to stabilize the core and/or alter the release kinetics of at least one pharmaceutically active agent.Type: ApplicationFiled: August 14, 2015Publication date: September 21, 2017Applicant: Dana-Farber Cancer Institute, Inc.Inventors: Zohreh Amoozgar, Michael Solomon Goldberg